NAMS
Price
$28.50
Change
+$2.21 (+8.41%)
Updated
Sep 26 closing price
Capitalization
3.21B
50 days until earnings call
SLNCF
Price
$1.45
Change
-$0.15 (-9.38%)
Updated
Sep 24 closing price
Capitalization
205.47M
Interact to see
Advertisement

NAMS vs SLNCF

Header iconNAMS vs SLNCF Comparison
Open Charts NAMS vs SLNCFBanner chart's image
NewAmsterdam Pharma
Price$28.50
Change+$2.21 (+8.41%)
Volume$756.02K
Capitalization3.21B
Silence Therapeutics
Price$1.45
Change-$0.15 (-9.38%)
Volume$1.1K
Capitalization205.47M
NAMS vs SLNCF Comparison Chart in %
Loading...
NAMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLNCF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NAMS vs. SLNCF commentary
Sep 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NAMS is a StrongBuy and SLNCF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 28, 2025
Stock price -- (NAMS: $28.50 vs. SLNCF: $1.45)
Brand notoriety: NAMS and SLNCF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NAMS: 86% vs. SLNCF: 231%
Market capitalization -- NAMS: $3.21B vs. SLNCF: $205.47M
NAMS [@Biotechnology] is valued at $3.21B. SLNCF’s [@Biotechnology] market capitalization is $205.47M. The market cap for tickers in the [@Biotechnology] industry ranges from $98.9B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NAMS’s FA Score shows that 1 FA rating(s) are green whileSLNCF’s FA Score has 1 green FA rating(s).

  • NAMS’s FA Score: 1 green, 4 red.
  • SLNCF’s FA Score: 1 green, 4 red.
According to our system of comparison, NAMS is a better buy in the long-term than SLNCF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NAMS’s TA Score shows that 4 TA indicator(s) are bullish while SLNCF’s TA Score has 3 bullish TA indicator(s).

  • NAMS’s TA Score: 4 bullish, 4 bearish.
  • SLNCF’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, NAMS is a better buy in the short-term than SLNCF.

Price Growth

NAMS (@Biotechnology) experienced а +6.78% price change this week, while SLNCF (@Biotechnology) price change was -9.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.00%. For the same industry, the average monthly price growth was +9.18%, and the average quarterly price growth was +54.60%.

Reported Earning Dates

NAMS is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Biotechnology (+4.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NAMS($3.21B) has a higher market cap than SLNCF($205M). NAMS YTD gains are higher at: 10.895 vs. SLNCF (-44.762). SLNCF has higher annual earnings (EBITDA): -84.82M vs. NAMS (-237.93M). NAMS has more cash in the bank: 739M vs. SLNCF (114M). SLNCF has less debt than NAMS: SLNCF (0) vs NAMS (328K). NAMS has higher revenues than SLNCF: NAMS (64M) vs SLNCF (27.2M).
NAMSSLNCFNAMS / SLNCF
Capitalization3.21B205M1,566%
EBITDA-237.93M-84.82M281%
Gain YTD10.895-44.762-24%
P/E RatioN/AN/A-
Revenue64M27.2M235%
Total Cash739M114M648%
Total Debt328K0-
FUNDAMENTALS RATINGS
SLNCF: Fundamental Ratings
SLNCF
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
26
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
87
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
NAMSSLNCF
RSI
ODDS (%)
Bearish Trend 3 days ago
56%
Bullish Trend 4 days ago
56%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
45%
Bullish Trend 3 days ago
55%
Momentum
ODDS (%)
Bullish Trend 3 days ago
52%
Bearish Trend 3 days ago
64%
MACD
ODDS (%)
Bullish Trend 3 days ago
62%
Bearish Trend 3 days ago
65%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
56%
Bearish Trend 3 days ago
65%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
58%
Bearish Trend 3 days ago
64%
Advances
ODDS (%)
Bullish Trend 24 days ago
75%
N/A
Declines
ODDS (%)
Bearish Trend 14 days ago
70%
N/A
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
60%
N/A
Aroon
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
66%
View a ticker or compare two or three
Interact to see
Advertisement
NAMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLNCF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WENRX67.420.53
+0.79%
Allspring Mid Cap Growth Fund - Cl R6
RIVSX18.830.11
+0.59%
River Oak Discovery
DEQAX14.520.08
+0.55%
BNY Mellon Global Equity Income - A
FCAKX48.220.26
+0.54%
Fidelity Capital Appreciation K
WASYX24.090.09
+0.38%
Macquarie Asset Strategy Fund Cl Y

NAMS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NAMS has been loosely correlated with CRDF. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if NAMS jumps, then CRDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NAMS
1D Price
Change %
NAMS100%
+8.41%
CRDF - NAMS
41%
Loosely correlated
+0.98%
BEAM - NAMS
41%
Loosely correlated
-0.52%
QURE - NAMS
39%
Loosely correlated
+3.15%
XNCR - NAMS
39%
Loosely correlated
+12.00%
OCUL - NAMS
38%
Loosely correlated
+2.37%
More

SLNCF and

Correlation & Price change

A.I.dvisor tells us that SLNCF and NAMS have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SLNCF and NAMS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLNCF
1D Price
Change %
SLNCF100%
N/A
NAMS - SLNCF
24%
Poorly correlated
+8.41%
SANA - SLNCF
22%
Poorly correlated
-1.47%
QLGN - SLNCF
21%
Poorly correlated
-8.33%
APGE - SLNCF
21%
Poorly correlated
+1.87%
ANIX - SLNCF
20%
Poorly correlated
+0.74%
More